RSS   Newsletter   Contact   Advertise with us
Post Online Media

EnPro Industries appoints Adele Gulfo to board

Share on Twitter Share on LinkedIn
Staff Writer | Charlotte, N.C., USA | Wednesday October 31, 2018 5:51AM ET
Adele GulfoEnPro Industries, an industrial conglomerate, announced that Adele Gulfo has been elected to the company’s board of directors.
Please disable your ad blocker for POST to be able to enjoy our free content.

Ms. Gulfo is Chief of Commercial Development of Roivant Sciences Ltd., a firm focused on rapidly developing innovative medicines through a novel form of industrial organization.

Prior to joining Roivant Sciences in May 2018, Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V., having previously served as Mylan’s Chief Strategy Officer.

Before joining Mylan, she served as the President and General Manager, Latin America of Pfizer Inc., covering operations in 24 countries, and before that as President and General Manager of the U.S. primary care business unit of Pfizer, and Country Chair for all US Biopharmaceuticals Operations.

Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals, including Vice President of Business Development and Healthcare Innovation.

Before joining AstraZeneca, Ms. Gulfo held a number of management positions with Warner-Lambert (which later merged with Pfizer), and as the Senior Director, Cardiovascular Marketing for that company implemented the marketing campaigns that established Lipitor as the market leader within two years of launch.

Ms. Gulfo holds a B.S. in Biology from Seton Hall University and an M.B.A. in Marketing from Fairleigh Dickinson University and has been awarded a number of patents.

She also serves on the board of directors and member of the Audit Committee of Bemis Company, Inc (BMS).


 LATEST MOVES FROM North Carolina 

POST Online Media Contact

 More inside POST